<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83570">
  <stage>Registered</stage>
  <submitdate>9/02/2009</submitdate>
  <approvaldate>11/05/2009</approvaldate>
  <actrnumber>ACTRN12609000241235</actrnumber>
  <trial_identification>
    <studytitle>Does a moderate dose fish oil intervention improve outcomes in older adults recovering from hip fracture?</studytitle>
    <scientifictitle>A Trial Assessing omega-3 fatty acids (N-3) as Treatment for Injury-induced Cachexia</scientifictitle>
    <utrn />
    <trialacronym>ATLANTIC trial</trialacronym>
    <secondaryid>ATLANTIC</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Elderly hip fracture patients with malnutrition</healthcondition>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Fractures</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>12-week well integrated, coordinated, individualized nutrition therapy plan consistent with estimated nutritional requirements and nutritional rehabilitation goals combined with moderate dose liquid fish oil intervention (20ml/d; 3g eicosapentanoic acid (EPA) and 2g docosahexanoic acid (DHA)</interventions>
    <comparator>The comparator group will receive the identical individualized 12-week nutrition therapy plan as the intervention group combined with low dose liquid fish oil (20ml/d; 0.3g EPA and 0.2g DHA)</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Health-related quality of life as assessed by the 'Assessment of Quality of Life' (AQoL) tool</outcome>
      <timepoint>At 6 and 12 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Body composition, assessed by dual-energy x-ray absorptiometry and bioelectrical impedance analysis</outcome>
      <timepoint>At 6 and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Physical function, assessed by timed chair stand test and assessment of physical autonomy by the 'Activities of Daily Living' tool</outcome>
      <timepoint>At 6 and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Levels of inflammatory markers including: C-reactive protein (CRP), Interleukin-1 (IL-1), Interleukin-6 (IL6) and tumour necrosis factor alpha (TNF-alpha)
Adherence to the fish oil intervention will be assessed by analysis of essential fatty acids (EPA ad DHA) from the erythrocyte phospholipid membrane</outcome>
      <timepoint>At 6 and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Nutritional status, assessed by the Mini Nutritional Assessment and percent weight change</outcome>
      <timepoint>At 6 and 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Resting energy expenditure (REE), assessed by a hand held portable indirect calorimeter.</outcome>
      <timepoint>At 6 and 12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Aged &gt;65 years
- PFF confirmed by radiology report
- Undergone surgery for fixation of hip fracture
- Reside within existing local service boundaries
- Community dwelling 
- Preliminary evidence of cachexia (CRP =6mg/L)
- At risk of significant weight loss (SNAQ score =14/20)</inclusivecriteria>
    <inclusiveminage>65</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- Severe cognitive impairment (MMSE &lt;18/30)

- PFF not fall-related, is pathological or is peri-prosthetic

- Initiation of anti-inflammatory drugs or corticosteroids within the previous two weeks

- Ingestion of  =2g total omega-3 daily as per fish FFQ

- Seafood allergy

- Life expectancy &lt;12 weeks

- Inability to communicate effectively due to blindness, deafness or lack of a translator

- Inability to provide informed consent

- Diagnosed with one of the following haemorrhagic stroke risk factors (Unstable hypertension, Atrial fibrillation, Inherited disorders such as polycystic kidney disease, Ehlers-Danlos syndrome type IV, neurofibromatosis type I, Marfan syndrome, moyamoya disease)

- Diagnosed with a bleeding disorders such as the following (von Willebrand disease or Haemophilia

- Receiving treatment doses of any antithrombotic agent 

- Those on dual anti-platelet function drugs or any anti-platelet drugs with exception to low dose aspirin.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence>Computerised sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Double-blinded trial</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/08/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>150</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Michelle Miller</primarysponsorname>
    <primarysponsoraddress>Department of Nutrition and Dietetics, Flinders University, GPO Box 2100, Adelaide SA 5001</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (NHMRC)</fundingname>
      <fundingaddress>National Health and Medical Research Council</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Professor Maria Crotty</sponsorname>
      <sponsoraddress>Department of Rehabilitation and Aged Care, Flinders University, GPO Box 2100, Adelaide SA 5001</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Associate Professor Robert Fraser</othercollaboratorname>
      <othercollaboratoraddress>Department of Medicine, Flinders University, GPO Box 2100, Adelaide SA 5001</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Professor Lynne Cobiac</othercollaboratorname>
      <othercollaboratoraddress>Department of Nutrition and Dietetics, Flinders University, GPO Box 2100, Adelaide SA 5001</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Professor Leslie Cleland</othercollaboratorname>
      <othercollaboratoraddress>Royal Adelaide Hospital, Rheumatology Unit, Frome Road, Adelaide SA 5000</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Professor Michael James</othercollaboratorname>
      <othercollaboratoraddress>Royal Adelaide Hospital, Rheumatology Unit, Frome Road, Adelaide SA 5000</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The anti-inflammatory properties of fish oil are well documented. Hip fracture is common and patients suffer significant unintentional weight and muscle loss leading to poor outcomes. An inflammatory response to the injury is a plausible mechanism for the lack of response observed in these patients when provided with best practice nutrition. This study aims to reduce the weight loss suffered by hip fracture patients by prescribing an intervention of individualised nutrition support and fish oil.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Adelaide Health Service Human Research and Ethics Committee</ethicname>
      <ethicaddress>Flinders Medical Centre, Bedford Park SA 5042</ethicaddress>
      <ethicapprovaldate>17/06/2010</ethicapprovaldate>
      <hrec>57/10</hrec>
      <ethicsubmitdate>1/02/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Human Research Ethics Committee</ethicname>
      <ethicaddress>Royal Adelaide Hospital, North Terrace, Adelaide, SA 5000</ethicaddress>
      <ethicapprovaldate>3/06/2010</ethicapprovaldate>
      <hrec>100515</hrec>
      <ethicsubmitdate>5/05/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Michelle Miller</name>
      <address>Department of Nutrition and Dietetics, Flinders University, GPO Box 2100, Adelaide SA 5001</address>
      <phone>+61 8 8204 5328</phone>
      <fax>+61 8 8204 6406</fax>
      <email>michelle.miller@flinders.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Michelle Miller</name>
      <address>Department of Nutrition and Dietetics, Flinders University, GPO Box 2100, Adelaide SA 5001</address>
      <phone>+61 8 8204 5328</phone>
      <fax>+61 8 8204 6406</fax>
      <email>michelle.miller@flinders.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Michelle Miller</name>
      <address>Department of Nutrition and Dietetics, Flinders University, GPO Box 2100, Adelaide SA 5001</address>
      <phone>+61 8 8204 5328</phone>
      <fax>+61 8 8204 6406</fax>
      <email>michelle.miller@flinders.edu.au</email>
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>